share_log

Roth MKM Initiates Coverage On Chemomab Therapeutics With Buy Rating, Announces Price Target of $7

Roth MKM Initiates Coverage On Chemomab Therapeutics With Buy Rating, Announces Price Target of $7

Roth MKM以买入评级开始对Chemomab Therapeutics进行报道,宣布目标股价为7美元
Benzinga ·  2023/10/06 08:56

Roth MKM analyst Dylan Dupuis initiates coverage on Chemomab Therapeutics (NASDAQ:CMMB) with a Buy rating and announces Price Target of $7.

Roth MKM分析师迪伦·杜普伊斯以买入评级开始对Chemomab Therapeutics(纳斯达克股票代码:CMMB)进行报道,并宣布目标股价为7美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发